ATOS
ATOSSA THERAPEUTICS, INC.
$2.46
-5.02%
$21.2M
No data for this timeframe.
Vol
Market Cap$21.2M
Cap SizeNano Cap
Analyst ConsensusStrong Buy (89%)
Inst. Holders17 funds
Inst. Value$5.3M
SEC Reports2
Recent Activity
Jun 12, 2026
SEC
Atossa Therapeutics is conducting a registered direct offering of 1,363,637 shares of common stock at $3.30 per share, b
424B5 — Impact 6/10
Jun 11, 2026
short_volume
Short Volume: ATOS — 55.0% short (0.5M / 0.9M)
Short: 471,498 | Exempt: 31,128 | TRF Vol: 857,024 | Short Ratio: 55.0% | Off-exchange volume (dark
May 12, 2026
Insider
Cigler Tessa was granted 10,000 shares
Director
May 12, 2026
Insider
Galli Stephen J was granted 10,000 shares
Director
May 12, 2026
Insider
Finn Jonathan was granted 10,000 shares
Director
Apr 16, 2026
SEC
Atossa Therapeutics resolved patent disputes with Intas Pharmaceuticals and Jina Pharmaceuticals related to Endoxifen in
8-K — Impact 7/10
Price Targets
$22.75
+824.8% upside
Strong Buy
Current $2.46
Low $20.00
Median $23.00
High $25.00
4 analysts
$20.00
$25.00
Analyst Ratings
2Strong Buy
6Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 10, 2026 | Ascendiant Capital | MAINTAIN | Buy → Buy |
| Mar 26, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-1.16 ▼ -0.6% | $-1.16 — $-1.16 | -10% YoY | 1 |
| Next Q | $-1.22 ▼ -18.1% | $-1.22 — $-1.22 | -16% YoY | 1 |
| Current FY | $-4.64 ▼ -7.7% | $-4.64 — $-4.64 | -15% YoY | 1 |
| Next FY | $-2.44 ▲ +17.0% | $-4.38 — $-0.49 | 48% YoY | 2 |
Latest Reports
BEARISH
424B5
6/10
Atossa Therapeutics is conducting a registered direct offering of 1,363,637 shares of common stock at $3.30 per share, b
Jun 12, 2026
BULLISH
8-K
7/10
Atossa Therapeutics resolved patent disputes with Intas Pharmaceuticals and Jina Pharmaceuticals related to Endoxifen in
Apr 16, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $1.8M | — |
| AMERIPRISE FINANCIAL INC | $1.3M | — |
| BlackRock, Inc. | $700.5K | — |
| RENAISSANCE TECHNOLOGIES LLC | $573.4K | — |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $289.3K | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 12, 2026 | Cigler Tessa | A | $0.00 |
| May 12, 2026 | Galli Stephen | A | $0.00 |
| May 12, 2026 | Finn Jonathan | A | $0.00 |
| May 12, 2026 | Remmel H. | A | $0.00 |
| May 12, 2026 | Chen Shu-Chih | A | $0.00 |
17 institutional holders with $5.3M total value (1,016,851 shares) as of 2026-Q1. Top holders: VANGUARD, AMERIPRISE, BlackRock,.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 349,096 | $1.8M | 34.3% | — |
| 2 | AMERIPRISE FINANCIAL INC | 255,134 | $1.3M | 25.1% | — |
| 3 | BlackRock, Inc. | 133,169 | $700.5K | 13.1% | — |
| 4 | RENAISSANCE TECHNOLOGIES LLC | 109,007 | $573.4K | 10.7% | — |
| 5 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 55,000 | $289.3K | 5.4% | — |
| 6 | VANGUARD FIDUCIARY TRUST CO | 52,235 | $274.8K | 5.1% | — |
| 7 | STATE STREET CORP | 39,761 | $209.1K | 3.9% | — |
| 8 | MORGAN STANLEY | 16,202 | $85.2K | 1.6% | — |
| 9 | Vanguard Global Advisers, LLC | 3,089 | $16.2K | 0.3% | — |
| 10 | JONES FINANCIAL COMPANIES LLLP | 2,061 | $9.7K | 0.2% | — |
| 11 | GROUP ONE TRADING LLC | 609 | $3.2K | 0.1% | — |
| 12 | ROYAL BANK OF CANADA | 644 | $3.0K | 0.1% | — |
| 13 | Rockefeller Capital Management L.P. | 353 | $1.9K | 0.0% | — |
| 14 | WELLS FARGO & COMPANY/MN | 296 | $1.6K | 0.0% | — |
| 15 | TD Waterhouse Canada Inc. | 103 | $525.00 | 0.0% | — |
| 16 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | 46 | $242.00 | 0.0% | — |
| 17 | Allworth Financial LP | 46 | $242.00 | 0.0% | — |
8 unique insiders with 10 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 12, 2026 | Cigler Tessa | Director | AWARD | 10,000 | — | — |
| May 12, 2026 | Galli Stephen J | Director | AWARD | 10,000 | — | — |
| May 12, 2026 | Finn Jonathan | Director | AWARD | 10,000 | — | — |
| May 12, 2026 | Remmel H. Lawrence | Director | AWARD | 10,000 | — | — |
| May 12, 2026 | Chen Shu-Chih | Director | AWARD | 10,000 | — | — |
| May 12, 2026 | Steinhart Richard I | Director | AWARD | 10,000 | — | — |
| Mar 27, 2026 | QUAY STEVEN C | President & CEO | AWARD | 65,000 | — | — |
| Mar 26, 2026 | Daniel Mark James | Chief Financial Officer | AWARD | 63,000 | — | — |
| Jan 20, 2026 | QUAY STEVEN C | President & CEO | AWARD | 331,674 | — | — |
| Jan 20, 2026 | QUAY STEVEN C | President & CEO | AWARD | 950,000 | $0.6030 | $572.9K |
2 SEC filing reports analyzed. Sentiment: 1 bullish, 1 bearish, 0 mixed, 0 neutral. Avg impact: 6.5/10.
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (89% buy). Based on 9 analysts: 2 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$22.75 mean target
+824.8% upside
Strong Buy (1.33)
$20.00 Low
$25.00 High
| Metric | Value |
|---|---|
| Current Price | $2.46 |
| Target Low | $20.00 |
| Target Mean | $22.75 |
| Target Median | $23.00 |
| Target High | $25.00 |
| # Analysts | 4 |
| Recommendation | Strong Buy (1.33) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-1.16 | $-1.16 | $-1.16 | -10.5% | -0.6% | 0↑ 2↓ | $0.0B | 0.0% | 1 |
| Next Q 2026-09-30 |
$-1.22 | $-1.22 | $-1.22 | -16.2% | -18.1% | 1↑ 1↓ | $0.0B | 0.0% | 1 |
| Current FY 2026-12-31 |
$-4.64 | $-4.64 | $-4.64 | -14.9% | -7.7% | 1↑ 1↓ | $0.0B | 0.0% | 1 |
| Next FY 2027-12-31 |
$-2.44 | $-4.38 | $-0.49 | 47.5% | +17.0% | 1↑ 0↓ | $0.0B | 0.0% | 2 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-1.160 | |
| 7d ago | $-1.275 | +0.115 |
| 30d ago | $-1.153 | -0.007 |
| 60d ago | $-1.070 | -0.090 |
| 90d ago | $-1.070 | -0.090 |
2 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 10, 2026 | Ascendiant Capital | MAINTAIN | Buy | Buy |
| Mar 26, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| May 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Apr 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| Mar 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| Feb 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| Jan 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 11, 2026
short_volume
Short Volume: ATOS — 55.0% short (0.5M / 0.9M)
Short: 471,498 | Exempt: 31,128 | TRF Vol: 857,024 | Short Ratio: 55.0% | Off-exchange volume (dark pool + OTC)
May 21, 2026
Clinical Trial
Effect of Oral (Z)-Endoxifen in Premenopausal Women With Measurable Breast Density
Phase Phase 2 — COMPLETED
May 11, 2026
earnings_calendar
ATOS Q1 2026 Earnings Scheduled — 2026-05-11
Mar 23, 2026
earnings_calendar
ATOS Q4 2025 Earnings After Market Close — 2026-03-23